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Abstract (N=185 words) 
 Hepatocarcinogenesis is tightly linked to liver fibrosis. Recently, two GWAS variants, 
MICA rs2596542 and DEPDC5 rs1012068 were identified as being associated with the 
development of HCV-induced hepatocellular carcinoma (HCC) in Japanese patients. The role of 
these variants on hepatic inflammation and fibrosis that are closely associated with HCC 
development is not known, nor are the biological mechanisms underlying their impact on the 
liver. Here, we demonstrate in 1689 patients with chronic hepatitis C (CHC) (1,501 with CHC 
and 188 with HCV-related HCC), that the MICA (T) allele, despite not being associated with 
HCC susceptibility, is associated with increased fibrosis stage (OR: 1.47, 95% CI: 1.05-2.06, 
p=0.02) and fibrosis progression rate (hazards ratio: 1.41, 95% CI: 1.04-1.90, p=0.02). The 
DEPDC5 variant was not associated with any of these phenotypes. MICA expression was down-
regulated in advanced fibrosis stages. Further, (T) allele carriage was associated with lower 
MICA expression in liver and serum. Transforming growth factor-β1 (TGF-β1) expression 
suppresses MICA expression in hepatic stellate cells. Our findings suggest a novel mechanism 
linking susceptibility to advanced fibrosis and subsequently indirectly to HCC, to the level of 







 Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular 
carcinoma (HCC) and liver transplantation, with an estimated 339,000 people dying annually 
from complications 1. Advanced liver fibrosis or cirrhosis represents the major risk factor for 
developing liver-related complications and mortality, but currently there are no approved anti-
fibrotic therapies 2. 
 The rate of liver fibrosis progression varies greatly according to disease etiology and also 
between individuals; the latter is at least partially attributable to genetic factors. In chronic HCV 
infection, host genetics play a pivotal role in shaping the immune response, virus-host 
interactions and ultimately the predilection to and progress of liver fibrosis 3,4. This risk is likely 
polygenic and dependent on multiple genetic and epigenetic factors since variations in single loci 
are usually of modest effect size and explain only a small fraction of the phenotype 5. This has 
led in the recent past to a shift towards the discovery of novel variants with limited effects which 
ultimately could guide the development of polygenic scores with high predictive value. 
 Two genome wide association studies (GWAS) have investigated the risk of HCV-related 
HCC in Japanese patients. The first identified a locus in the 5` flanking region of the MHC class 
I-related chain A (MICA) on 6p21.33 (rs2596542) to be strongly associated with HCC and the 
progression from CHC to HCC 6. MICA is a ligand for natural-killer group 2 member D 
(NKG2D), a highly conserved C-type lectin-like membrane glycoprotein and one of the major 
activating receptors on NK cells 7. The second GWAS identified a susceptibility locus near 
DEPDC5 (rs1012068) 8. The function of DEPDC5 is not well understood, but has been linked 
with hereditary forms of epilepsy 9, bladder cancer 10 and malignant glioblastomas 11. 
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 Complicating the interpretation of these findings however is that HCC development in 
chronic HCV infection is tightly linked to hepatic fibrosis with 90% of cases arising in cirrhotic 
livers 12. Hence, risk variants that predispose to fibrosis could be associated with HCC formation 
without direct causality and disentangling the two is problematic. In this regard, little is known 
about the potential effect of variants in MICA and DEPDC5 on liver fibrosis since both GWAS 
were done in patients in whom liver biopsy was not available. Importantly, functional data on the 
role of these variants with regard to both fibrosis pathways or HCC development are limited. The 
available literature is also restricted to Japanese populations with chronic HCV infection and 
HCC, while a single report in Caucasians 13 suggests that DEPDC5 but not MICA is associated 
with fibrosis progression. 
 Here we sought to dissect the role of MICA rs2596542 and DEPDC5 rs1012068 to liver 
fibrosis and to HCV-related HCC. To do this, these variants were assessed in 1,501 patients with 
CHC of Caucasian ancestry in whom liver biopsy was available and were compared to 188 
patients with CHC-related HCC. We undertook functional studies to explore the mechanisms 







 The clinical, demographic and biochemical characteristic of the patients in the cohort 
with chronic HCV infection (n=1501) are presented in supplementary table 1. The genotype 
distribution of MICA rs2596542 and DEPDC5 rs1012068 was in Hardy-Weinberg equilibrium 
and is presented in supplementary table 2. The minor allele frequency (MAF) for the two 
variants was similar to that observed in a healthy European population from the 1000 genome 
project (http://browser.1000genomes.org), which has some difference from the Japanese 
population. 
Association of MICA rs2596542 and DEPDC5 rs1012068 with viral and clinical 
characteristics 
 To explore if baseline clinical variables differ between chronic HCV patients according 
to MICA rs2596542 or DEPDC5 rs1012068 genotype, we examined the association of the 
genotypes with baseline clinical variables; the results are presented in supplementary tables 3 
and 4, respectively. There was no evidence of association between either rs2596542 or 
rs1012068 genotype with any clinical variable (i.e. age, BMI, baseline levels of ALT, AST, 
GGT, ALP, platelets, leukocytes, HCV-RNA quantification, gender frequency or HCV genotype 
distribution). 
MICA rs2596542, but not DEPDC5 rs1012068 is associated with fibrosis severity 
 We next assessed the association between MICA rs2596542 and DEPDC5 rs1012068 and 
liver damage (hepatic inflammation and fibrosis). The distribution of rs2596542 and rs1012068 
genotypes according to histological features is depicted in Figure 1.  
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 First, we examined the association of the two genetic variants with fibrosis. In 
multivariate analyses adopting an additive model adjusted for age, gender, BMI, HCV genotype 
and alcohol intake, MICA rs2596542 was significantly associated with stage of fibrosis (adjusted 
estimate, 0.072, SE, 0.051; p=0.01) (Supplementary Table 5). In further analysis when the 
cohort was segregated into those with mild (F0–1) versus advanced fibrosis (F2–4), carriage of 
each copy of the MICA rs2596542 (T) allele was associated consistently with a significant 
increased risk of advanced fibrosis, independent of age, gender, BMI, HCV genotype and 
alcohol intake  (OR: 1.47, 95% CI: 1.05-2.06, p=0.02) (Supplementary Table 6). Similarly, 
rs2596542 was associated with severe fibrosis (F3-F4) (OR: 1.43, 95% CI: 1.03-1.99, p=0.03). 
On the contrary, we did not observe any association between DEPDC5 rs1012068 and stage of 
fibrosis (Supplementary Table 5); the distribution of rs1012068 genotypes was also not 
significantly different according to the presence or absence of significant or severe fibrosis 
(Supplementary Table 6).  
 We next examined the association of the two genetic variants with hepatic inflammation 
defined by liver histopathology scored according to METAVIR. Neither MICA rs2596542 nor 
DEPDC5 rs1012068 demonstrated any association with inflammation grade (Supplementary 
Table 5). No association was also observed when the cohort was dichotomized into absent/mild 
(A0-A1) versus moderate/severe (A2-A3) inflammation (Supplementary Table 6). 
Consistently, no difference was noted in serum liver enzymes (ALT or AST; as indices of liver 
injury) according to rs2596542 or rs1012068 (supplementary tables 3 and 4, respectively). 
Association between MICA rs2596542 and fibrosis progression 
 To validate these observations, we undertook analysis in the 815 patients from the entire 
cohort with chronic HCV infection and a known duration of infection. This allowed assessment 
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of the relationship to fibrosis progression without the inherent biases of cross sectional analyses. 
The baseline characteristics of the cohort were similar among subjects included and not included 
in the fibrosis progression sub-analysis (Supplementary Table 7). As the fibrosis progression 
rate (FPR) may not be constant over time 14, we used Cox-proportional hazards analysis. In this 
analysis, rs2596542 was associated with an increased hazard of progression to significant 
fibrosis (≥ F2) in a multivariate model that included age, gender, BMI and HCV genotype 
(hazards ratio: 1.41, 95% CI: 1.04-1.90, p=0.02 per each T allele). In contrast, DEPDC5 
rs1012068 was not associated with FPR (hazards ratio: 1.06, 95% CI: 0.76-1.48, p=0.7) 
(Supplementary Table 8). In sum, these data suggest that MICA rs2596542 but not DEPDC5 
rs1012068 is associated with fibrosis severity and fibrosis progression.  
Chronic HCV infection increases hepatic MICA expression 
 In the subsequent studies reported below, we sought to define the functional basis for the 
association of variants in MICA to liver fibrosis. The expression of MICA is low in healthy 
tissues but can be induced by cellular stressors such as viral infection 15; the effect of HCV 
infection on hepatic MICA expression is not known. We therefore compared MICA expression 
in liver from patients with HCV and from control, non-infected subjects. RT-PCR demonstrated 
increased MICA mRNA expression in patients with chronic HCV infection (Figure 2a). We 
then assessed MICA expression in the JFH1/Huh7 in vitro model of replicating HCV. 
Consistently, Huh7 cells infected with the JFH1 strain of HCV demonstrated a 3-fold 
upregulation of MICA mRNA compared to control uninfected cells (Figure 2b), p<0.05). 
 The biological effect of MICA in HCV-infected liver likely reflects a complex interaction 
between the different cell types within an inflamed liver that ultimately leads to fibrosis. Hence, 
we examined the expression of MICA in four primary human hepatic cell types, namely 
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hepatocytes, Kupffer cells, hepatic sinusoidal endothelial cells and stellate cells by real time 
PCR. The highest expression of MICA was in stellate cells followed by Kupffer cells, while 
sinusoidal cells and hepatocytes had low expression (Supplementary Figure 1).  
Membranous and soluble MICA levels associate with MICA genotype and fibrosis severity 
 Whether the MICA risk allele is associated with altered membrane bound (mMICA) 
expression in liver tissue from patients with chronic HCV infection is not known as all available 
current data are based on the soluble form (sMICA) present in serum 6,16. As shown in Figure 
2c, we observed a significant association between rs2596542 genotype and MICA mRNA 
expression; the (T) allele associated with lower hepatic MICA mRNA in the 94 patients with 
available liver tissue (P = 0.01, p=0.02 after adjustment for age and sex).  
 We then measured soluble MICA (sMICA) by ELISA in serum samples from a sub-
cohort of 214 chronic HCV infection patients; their characteristics are summarized in 
Supplementary Table 9 and matched the overall cohort. Similar to mMICA, compared to 
patients harboring the MICA rs2596542 CC genotype, sMICA levels were significantly reduced 
in those with the risk T allele (Figure 2d). We determined the correlation of mMICA to sMICA 
in 58 patients in whom paired liver and serum data was available. In this analysis, levels of 
sMICA associated with the expression of mMICA (p = 0.0001) (Figure 2e).  
 In total, MICA expression is upregulated in HCV infection in an rs2596542 genotype 
dependent manner with individuals carrying rs2596542 (T) expressing lower levels of mMICA 
and sMICA. This suggests that differences in expression levels of mMICA according to 
genotype are not a consequence of differing shedding rates of MICA. 
MICA expression and liver fibrosis 
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 The overall contribution of the MICA/NKG2D pathway to fibrosis is unclear. 
Interestingly and consistent with the genetic data, hepatic MICA expression was significantly 
lower in subjects with significant hepatic fibrosis (F2–F4) compared to those with no or mild 
hepatic fibrosis (F0/1) (n=94) (Figure 2f). MICA expression did not correlate with hepatic 
inflammation, liver enzymes, HCV-RNA levels and genotype, age or gender. Similarly, sMICA 
levels were decreased in patients with significant fibrosis compared to those without, though this 
was not significant (supplementary Figure 2). 
MICA expression is regulated by TGF-β1 in hepatic stellate cells 
 We next thought to explore how differential expression of hepatic MICA could be linked 
to fibrosis progression. Hepatic stellate cells (HSC) are responsible for the deposition of 
extracellular matrix that is evident histologically as fibrosis 17 and as we have shown, also have 
the highest expression of MICA. Killing of activated HSCs by NK cells to ameliorate liver 
fibrosis is in part by a MICA/NKG2D-dependent manner 18. Thus, we investigated the regulation 
of MICA expression on HSCs in a fibrotic context. 
 Surface expression of MICA has been reported to be down-regulated by TGF-β1 19, an 
established growth factor mediating liver injury and fibrosis 12. Hence, we characterized TGF-β1 
mediated regulation of MICA expression on HSCs. We first assessed expression of TGF-β1 
mRNA after HCV infection in vitro using qRT-PCR. This revealed a significant increase in 
TGF-β1 in HCV-infected JFH-1/Huh7 cells compared to non-infected cells (Figure 3a). 
Consistently, we observed increased TGF-β1 transcription in liver from chronic HCV infected 
liver samples compared to healthy controls (Figure 3b). Within the chronic HCV infection 
group, the expression of TGF-β1 mRNA was significantly up-regulated with advancing of 
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fibrosis stage (Figure 3b) and this was consistently observed in the sub-cohort with available 
serum described above (n=214) (Figure 3c). 
 Given these results, we examined for the effect of TGF-β1 on MICA expression on a 
human HSC-derived cell line (LX2). We observed a marked repression of MICA mRNA 
transcripts in TGF-β1 stimulated LX2 cells (Figure 3d), as well as reduced surface expression of 
MICA, by flow cytometry (Figure 3e). For confirmation that this effect was mediated through 
the TGFβR, we used a specific pharmacological inhibitor of TGFβR-I/II (using LY2109761) and 
this as expected, reversed the inhibitory effect of exogenous TGFβ1 on MICA expression 
(Figure 3d and e). To characterize the role of endogenous HSC-derived TGF-β1 in the 
regulation of MICA expression, we used LX2 cells treated with LY2109761 and demonstrated a 
significant induction of MICA mRNA transcripts and surface expression levels (Figure 3d and 
e). 
 Lastly, previous reports have observed a positive effect of TGF-β1 treatment on the 
expression of some proteases including MMP-9. Since MICA surface expression can be 
modulated at a post-translational level by proteolytic cleavage 20, we asked whether shedding of 
sMICA was enhanced in TGF-β1 stimulated cells, thus contributing to the attenuation of surface 
expression on these cells. To this end, we measured sMICA in cell culture supernatant and 
showed that the level of sMICA released by TGF-β1 stimulated cells was not different compared 
with control cells suggesting that cleavage of MICA is not mediated by TGF-β1-dependent 
proteases (Figure 3f).  
MICA polymorphism is not associated with HCC 
 As MICA was originally discovered as a risk locus for HCC in Japanese patients, we 
investigated the role of MICA in hepatocarcinogenesis. We compared MICA genotype 
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distribution in patients with chronic HCV-HCC (n=188) to non-HCC from the entire chronic 
HCV infection cohort described above (n=1,501; Supplementary Table 10). We observed no 
difference in MICA rs2596542 distribution between subjects with HCC and those without. 
Because HCC mainly occurs in the context of cirrhosis, we undertook similar analysis restricting 
the comparison to those with HCC versus those with chronic HCV infection and cirrhosis 
(n=210). Again, no difference in MICA rs2596542 distribution was observed between subjects 
with HCC and those with cirrhosis (p=0.77). Results were not changed after adjustment for age 
and sex. These findings imply that MICA rs2596542 polymorphism is unlikely to be directly 





 Here, we report that a genetic variant in MICA originally identified by GWAS as a risk 
variant for susceptibility to HCV-associated HCC in Japanese patients 6 associates with fibrosis 
severity and progression, but not with HCC. Functionally our data suggest that the association 
with HCC is plausibly mediated by indirect effects through modulation of fibrosis risk. 
Following the data for effects on fibrosis progression, we show MICA genotype-dependent 
reductions in hepatic MICA gene expression and soluble MICA protein levels. Tying these 
findings to fibrosis, TGF-β1 was increased with advancement of fibrosis and there was a 
corresponding reduction in MICA expression. In vitro, TGF-β1 treatment resulted in MICA 
transcriptional and surface protein repression on HSC cells. These effects we propose leads to an 
increased likelihood of fibrosis in those with the risk genotype. Our findings therefore suggest a 
molecular explanation for the association of rs2596542 with liver fibrosis (Figure 4).  
 Consistent with the present findings in the setting of chronic HCV infection, a recent 
report suggests that MICA polymorphisms (MICA*012:01/02, MICA*017 and MICA*027) are 
associated with liver fibrosis in schistosomiasis 21. It is noteworthy that in the original GWAS 
report of MICA in HCV-related HCC, Kumar et al., did not use HCV-related cirrhosis without 
HCC as their control cohort, masking any potential confounding by fibrosis 6. This and the 
failure to find an association with MICA in a similar Japanese study published 2 months later 8, 
as well as the functional data we provide, suggest that the reported association with HCC 
actually relates to liver fibrosis risk.  
 MICA is a stress inducible protein present at very low levels in healthy tissues, but can be 
induced by cellular stresses such as viral infection 15. Consistently, we demonstrated increases in 
MICA expression during the early stages of HCV infection, while it decreases with increasing 
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fibrosis in an rs2596542 genotype dependent manner. Furthermore, the (T) risk allele correlated 
with lower mMICA in liver. Consistent with other groups 6,16, we demonstrated decreased 
expression levels of sMICA in the serum of patients with the (T) rs2596542 allele.  
 The mechanisms that link MICA genotypes with fibrosis risk have not been previously 
elucidated. MICA is a ligand for the activating NK cell receptor NKG2D and this interaction 
shapes the anti-fibrotic capacity of NK-cells via elimination of activated HSCs 18,22 We verified 
that HCV infection is associated with an increase in TGF-β1 expression in liver 23 and the latter 
induces marked repression of MICA expression in HSC. This suggests that MICA genotype 
might be associated with alterations in TGF-β1 (through as yet undefined mechanisms) and may 
underlie the accelerated fibrosis we observed.  
 We did not observe any association between DEPDC5 rs1012068, the other variant 
identified by GWAS as a risk variant for HCC 8, with either fibrosis or HCC. A large Japanese 
study of 2,266 HCV patients who had eradicated HCV and with long term follow up to 20 years, 
was also unable to find any association between DEPDC5 SNPs at rs1012068 and the 
cumulative risk of HCC 24. Some studies have reported an association of DEPDC5 with fibrosis 
but with opposite effects of the risk allele 13,25,26. A recent smaller study conducted in Europeans 
suggested an association between DEPDC5 rs1012068 but not MICA rs2596542 and risk of 
cirrhosis in chronic HCV infection 13. The reasons for the discrepancy between our study and 
this work are unclear, but may relate to differences in baseline characteristics and that the 
association analyses for fibrosis were performed differently, as those authors compared F0-F1 
vs. F4. Interestingly, in that study, MICA rs2596542 showed a tendency for significance with 
cirrhosis (p=0.07) in the discovery cohort (n=477) but was not investigated in the validation 
cohort. The function of DEPDC5 in liver needs to be defined. 
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 Our study has some limitations, including the fact that the sample size of the PCR and 
ELISA sub-cohorts was relatively modest. In addition, whether MICA rs2596542 is the 
functional polymorphism or if there are other variants in linkage disequilibrium and the detailed 
functional mechanisms for the effects are still not fully understood.  
 In conclusion, we have demonstrated that MICA rs2596542 is associated with liver 





Figure 1: Association of MICA rs2596542 and DEPDC5 rs1012068 with inflammation, 
fibrosis stage. Association of MICA rs2596542 with fibrosis stage (a) and inflammation (b) and 
DEPDC5 rs1012068 with fibrosis stage (c) and inflammation (d) in the CHC cohort (n=1501). P-
values are univariate and provided for the additive model of inheritance. MICA rs2596542 (T) 
allele is the risk allele, the same risk allele in the GWAS by Kumar et al (6). DEPDC5 
rs1012068 (G) allele is the risk allele, the same risk allele in the GWAS by Miki et al (8). 
Figure 2: Hepatic and serum MICA expression. Relative hepatic MICA mRNA expression in 
94 patients with chronic hepatitis C virus infection and 28 controls (a); relative MICA mRNA 
expression in Huh7 cells infected with the JFH1 strain hepatitis C virus as compared to mock 
infected control cells (b); correlation between MICA rs2596542 genotype and hepatic MICA 
mRNA (c) and soluble MICA levels (n =214) (d). The x axis shows the genotypes at rs2596542 
and the y axis shows MICA expression level relative to GAPDH by quantitative real-time PCR 
or the concentration of soluble MICA in pg/ml by ELISA, respectively. The level of hepatic 
MICA mRNA correlates positively with serum soluble MICA levels in a sub-cohort of CHC 
with available RNA and serum (n=58) (e); hepatic MICA mRNA according to hepatic fibrosis 
(f). The x axis shows hepatic fibrosis dichotomized as absent/mild (METAVIR stage F0–F1) or 
moderate/severe (METAVIR stage F2–F4), and the y axis shows hepatic MICA expression. The 
number of independent samples tested in each group is shown below the figure and P value was 
calculated using the two-tailed Student's t-test or ANOVA test with Tukey test for correction for 
multiple comparisons.  
Figure 3: Transforming growth factor beta influences MICA expression. Relative TGF-β1 
mRNA expression in Huh7 cells infected with the JFH1 strain of the hepatitis C virus compared 
to mock infected control cells (a); relative hepatic TGF-β1 mRNA expression in 94 patients with 
chronic hepatitis C virus infection and 28 controls according to fibrosis stage (b); serum 
concentration of TGF-β1 in pg/ml levels according to hepatic fibrosis (n=214) (c); MICA mRNA 
expression and protein levels at the hepatic stellate cell surface modulation by TGF-β1. MICA 
mRNA expression was assessed in control, TGF-β1 (2ng/ml) with or without LY2109761 (a 
TGFβR-I/II inhibitor) (100nM, was added 90 minutes before TGF-β1), or LY2109761 (100nM) 
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treated cells for 24 hours by real-time PCR (d), or 48 hours for flow cytometry (e); the level of 
soluble MICA was assessed in the supernatant of control or TGF-β1 (2ng/ml) treated LX2 cells 
for 24 and 48 hours by ELISA (f). Results are expressed, as mean ± sem (n = 3) and P value was 
calculated using the two-tailed Student's t-test or ANOVA test with Tukey test for correction for 
multiple comparisons. *P < 0.05,** P<0.001, *** P<0.0001.  
Figure 4: Proposed model for the effect of MICA rs2596542 in modulating liver fibrosis 
risk. Patients carrying the MICA risk genotype have low hepatic and serum MICA expression. 






 The study comprised 1689 consecutive patients (1,501 with CHC and 188 with HCV-
related HCC) from the International Liver Disease Genetics Consortium (ILDGC) database. 
Details of the cohort and inclusion criteria have been reported 27-29. Briefly, all subjects who had 
a liver biopsy with scoring for fibrosis stage and disease activity before anti-viral treatment, and 
genomic DNA were included. For those with CHC, those with HCV RNA serum positivity of 
Self-reported Caucasian descent were included. Patients were excluded if they had evidence of 
co-infection with other hepatitis viruses, other liver diseases by standard tests or current or 
previous hepatic decompensation. Diagnosis of HCC was based on the EASL–EORTC Clinical 
Practice Guidelines 30. 
 The study protocol was conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. Ethics approval was obtained from the Human Research Ethics Committees of the 
Western Sydney Local Health District and the University of Sydney. All other sites had ethics 
approval from their respective ethics committees and study was performed according to the 
recommendations of the centers involved. Written informed consent for genetic testing was 
obtained from all participants. 
Clinical and laboratory assessment 
 The following data were collected at time of liver biopsy from all patients: gender, age, 
ethnicity, recruitment center, alcohol intake (g/day), body mass index (BMI) and routine 




Methods to estimate the duration of infection  
 Fibrosis progression was examined in 815 chronic HCV infection patients with a reliable 
estimated duration of infection, as previously reported 31,32. Briefly, for subjects with a history of 
injecting drug use, the time of infection was estimated using the reported “first year of injection”. 
For patients with a history of blood transfusion, the onset of infection was assumed to be the year 
of transfusion. For patients with a history of occupational exposure, the onset of infection was 
assumed to be the first year of needle stick exposure. The duration of infection was calculated by 
subtracting the estimated age at infection from age at biopsy. 
Genotyping  
 Genotyping for MICA rs2596542 and DEPDC5 rs1012068 was contracted to the 
Australian Genome Research Facility (AGRF; QLD, Australia). 1051 samples were genotyped 
using the Sequenom MassARRAY system and iPLEX Gold chemistry while 638 samples were 
genotyped using the TaqMan SNP genotyping allelic discrimination method (Applied 
Biosystems, Foster City, CA, USA). All genotyping was blinded to clinical variables. 
Liver Histopathology 
 Liver histopathology was scored according to METAVIR33. Fibrosis was staged from F0 
(no fibrosis) to F4 (cirrhosis). Necroinflammation (A) was graded as A0 (absent), A1 (mild), A2 
(moderate) or A3 (severe). The inter-observer agreement between pathologists was studied 
previously and was good (κ = 77.5) for METAVIR staging using κ statistics 34. 
Other Methods 
Methods for cell culture, real-time PCR, ELISA and flow Cytometry are described in Materials 




 Statistical analyses were performed using the statistical software package SPSS for 
Windows, version 21 (SPSS, Chicago, IL). All tests were two-tailed and p values <0.05 were 
considered significant. Details of statistical analyses are described in the Materials and Methods 
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